• Explore /
  • Poster
  • / Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma.

Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma.

Abstract Poster

Authors

null

Lin Gui

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China

Lin Gui , Ying Cheng , Huaqing Wang , Junning Cao , Zhenling Li , Lei Zhang , Yuhuan Gao , Yufu Li , Weijie Xu , Xiang Li , Xiaoyan Ke , Hongmei Jing , Qingyuan Zhang , Yaming Xi , Tingbo Liu , Zhen Wang , Yajie Gao , Qin Pan , Liqun Zou , Yuankai Shi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03934567

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7513)

DOI

10.1200/JCO.2022.40.16_suppl.7513

Abstract #

7513

Poster Bd #

167

Abstract Disclosures

Similar Posters

First Author: Andrew David Zelenetz

First Author: Zhong Zheng

First Author: Michael Dickinson

First Author: Yuka Kato